ClinicalTrials.gg
CompletedNCT03272646NPSUpdated Sep 5, 2017

Prognostic Performance of the Naples Prognostic Score

An observational study in Nutritional and Metabolic Diseases and Oncologic Disorders, sponsored by University of Campania Luigi Vanvitelli. Completed. Per ClinicalTrials.gov, last updated 2017-09-05.

Sponsored by University of Campania Luigi Vanvitelli · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
477
Sex
All
01

Study summary

To investigate the prognostic performance of the Naples Prognostic Score in gastric cancer patients undergoing surgery

Read the detailed description

The outcome of oncological patients is related not only to the tumor status but also to the host. Particularly the patient's immune and nutritional status have been recently associated with short- and long-term outcome in gastric and other cancers. In addition, there is growing evidence that systemic inflammation plays a crucial role in the carcinogenesis and progression of gastric cancer. The neutrophil to lymphocyte ratio (NLR), and, more recently, the lymphocyte to monocyte ratio (LMR) have been shown to be independently correlated with prognosis in patients with gastric cancer who underwent surgery, and preoperative albumin and cholesterol levels seem to be adequate mirrors of the nutritional status of the host.

The investigators have already demonstrated that a new scoring system, which they called Naples prognostic score (NPS), based on a composite score of albumin and cholesterol concentrations, along with NLR and LMR is a simple tool strongly associated with long-term outcome in patients undergoing surgery for colorectal cancer.

The aim of this study is to assess the correlation between the NPS and clinicopathological characteristics, postoperative complication rate and long-term outcome in patients undergoing surgery for gastric cancer. Furthermore, the new prognostic scoring system will be compared with previously developed ones and the current TNM staging system to evaluate its performance.

All patients who underwent surgery for proven gastric adenocarcinoma at the Division of Surgical Oncology of the Gastrointestinal Tract of the University of Campania (Naples, Italy), from January 2000 to December 2015 will be enrolled in the present study.

02

Conditions studied

  • Nutritional and Metabolic Diseases
  • Oncologic Disorders

Keywords

  • Gastric Cancer
03

In context

Nutritional and Metabolic Diseases

72 studies on the registry are indexed under Nutritional and Metabolic Diseases; 20 are open to participants now.

This study's enrollment of 477 is above the median of 338 across 18 observational studies indexed under Nutritional and Metabolic Diseases.

Browse Nutritional and Metabolic Diseases studies →

Lead sponsor

University of Campania Luigi Vanvitelli is the lead sponsor of 174 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with proven gastric adenocarcinoma undergoing surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all patients undergoing surgery at our institution for proven gastric adenocarcinoma will be enrolled in the present study

Exclusion criteria

Exclusion Criteria:

  • Patients with lower esophageal adenocarcinoma or cancer crossing the esophagogastric junction with its epicenter in the proximal 2 cm of stomach, which were taken apart from stomach cancers in the last two AJCC cancer staging editions, will be excluded.
  • Patients with ongoing infections, concomitant immune-mediated diseases, or on drugs capable of affecting neutrophil and/or lymphocyte counts (e.g., , , etc.) will be excluded from the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
477 participants (actual)
Target follow-up
17 Years
Patient registry
Yes

Groups and cohorts

  • Group 1 or NPS = 0

    Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.

    Procedure: surgery

  • Group 2 or NPS >0 and < 3

    Patients undergoing surgery with NPS between 1 or 2

    Procedure: surgery

  • Group 3 or NPS > 2

    Patients undergoing surgery with three or four alterations

    Procedure: surgery

Interventions

  • Proceduresurgery

    gastric resection or total gastrectomy

    Also known as: radical surgery

06

What researchers measure

Primary outcomes

  1. Prognostic performance of NPS.

    Corrlation between preoperative NPS and outcome (i.e. overall survival in all patients, and disease-free survival in radically resected patients). The prognostic performance of NPS will be compared to that of the prognostic nutritional index (PNI), the controlling nutritional status (CONUT) score, the systemic inflammation score (SIS), and the TNM staging system.

    Time frame: through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All data will be made available by contacting the principal investigator.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: at the end of the study

Access criteria: gennaro.galizia@unicampania.it

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2000 to primary completion in Dec 2015, 191 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2017
First posted
Sep 5, 2017
StartActual
Jan 1, 2000
Primary completionActual
Dec 31, 2015
CompletionActual
Jun 30, 2017
Last update
Sep 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03272646
Responsible party
Gennaro Galizia (Full Professor of Surgery, University of Campania Luigi Vanvitelli) — Principal investigator
First posted
Sep 5, 2017
Start date
Jan 1, 2000
Primary completion
Dec 31, 2015
Completion
Jun 30, 2017
Last update
Sep 5, 2017

Study contacts

Gennaro Galizia, MD
principal investigator · University of Campania 'Luigi Vanvitelli'

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion